title: Combined endothelin receptor blockade evokes enhanced vasodilatation in patients with atherosclerosis.
abstract: Endothelin (ET)-1 causes vasoconstriction via ET(A) and ET(B) receptors located on vascular smooth muscle cells and vasodilatation via ET(B) receptors on endothelial cells. Studies in vitro indicate an upregulation of ET(B) receptors in atherosclerosis. The present study investigated the vascular effects evoked by endogenous ET-1 in atherosclerotic patients. Forearm blood flow (FBF) was measured with venous occlusion plethysmography in 10 patients with atherosclerosis and in 10 healthy control subjects during intra-arterial infusion of selective ET receptor antagonists. The ET(B) receptor antagonist BQ788 evoked a significant increase in FBF (31+/-13%) in the patients, whereas a 20+/-9% reduction was observed in the control subjects. The ET(A) receptor antagonist BQ123 combined with BQ788 evoked a marked increase in FBF (102+/-25%) in the patients compared with no effect in the control subjects (-3+/-9%, P<0.001 versus patients). The ET(A) receptor antagonist BQ123 increased FBF to a similar degree in patients (39+/-11%) as in control subjects (41+/-11%). The increase in FBF evoked by selective ET(A) receptor blockade was significantly (P<0.05) less than that evoked by combined ET(A)/ET(B) receptor blockade in the atherosclerotic patients. These observations suggest an enhanced ET-1-mediated vascular tone in atherosclerotic patients, which is at least partly due to increased ET(B)-mediated vasoconstriction.
authors.affiliation: Department of Cardiology, Karolinska Hospital, and the Department of Clinical Physiology, Huddinge Hospital, Huddinge, Sweden. Felix.Bohm@medks.ki.se
authors.forename: Felix
authors.initials: F
authors.lastname: Böhm
authors.forename: Gunvor
authors.initials: G
authors.lastname: Ahlborg
authors.forename: Bo-Lennart
authors.initials: BL
authors.lastname: Johansson
authors.forename: Lars-Olof
authors.initials: LO
authors.lastname: Hansson
authors.forename: John
authors.initials: J
authors.lastname: Pernow
mesh_terms: D000959:Antihypertensive Agents / Q000494:pharmacology; D001161:Arteriosclerosis / Q000503:physiopathology*; D016022:Case-Control Studies; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000502:physiology*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology; D005542:Forearm / Q000098:blood supply; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D012039:Regional Blood Flow / Q000187:drug effects; D015854:Up-Regulation; D014664:Vasodilation / Q000502:physiology*
chemical_list: D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D009842:Oligopeptides; D010456:Peptides, Cyclic; D010880:Piperidines; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; C086539:BQ 788; C072247:cyclo(Trp-Asp-Pro-Val-Leu)